Search

Displaying results 2021 - 2030 of 5506 in total
  1. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].

  2. Drug

    Levobetaxolol

    go.drugbank.com/drugs/DB09351
    Approved

    It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.

  3. Drug

    Tofacitinib

    go.drugbank.com/drugs/DB08895
    ApprovedInvestigational

    It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.

  4. Drug

    Pentamidine

    go.drugbank.com/drugs/DB00738
    ApprovedInvestigational

    It may cause diabetes mellitus, central nervous system damage, and other toxic effects.

  5. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)

  6. Drug

    Turpentine

    go.drugbank.com/drugs/DB11120
    Approved

    It is used as a solvent and base material in organic synthesis reactions.

  7. Drug

    Propylthiouracil

    go.drugbank.com/drugs/DB00550
    Approved

    It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)

    Products: PROPYL TABLET 50MG, PROPYLTHIOURACIL ACTAVIS TABLET 50MG
  8. Drug

    Tubocurarine

    go.drugbank.com/drugs/DB01199
    ApprovedWithdrawn

    [A216028] It was first isolated by Harold King in 1935 and was used clinically to induce neuromuscular blockade during surgeries, particularly those involving the abdomen.

  9. Drug

    Daleuton

    go.drugbank.com/drugs/DB00154
    InvestigationalNutraceutical

    A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.

  10. Drug

    EVT 201

    go.drugbank.com/drugs/DB05721
    Investigational

    EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.